Provention plans IPO, reveals MacroGenics deal

Autoimmune and infectious disease company Provention Bio Inc. (Lebanon, N.J.) proposed to raise up to $50 million in an IPO underwritten by MDB Capital Group. The company's pipeline includes several candidates in-licensed from other companies and

Read the full 365 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE